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Abstract: Leishmania exhibit many unusual features, one of which is the pteridine 
metabolic pathway essential for the growth for these parasites. Leishmania have evolved 
a complex and versatile pteridine salvage network capable of scavenging a wide array of 
conjugated and unconjugated pteridines.  
The L. major PTR1 gene was cloned into pcDNA3 digested with KpnI and BamHI. The 
gene was cloned antiparallel to the promoter and named pcDNA-Rptr. L. major 
promastigotes were divided into two groups. One group was transfected with 50 μg of 
pcDNA-Rptr, whereas the other group was electroporated with pcDNA3. Mentioned cells 
were cultured and plated onto semi-solid media. 
Western blotting was performed on extracts from transfected promastigotes of L. major 
using an leishmania major PTR1 antibody. The PTR1 protein was not expressed in 
pcDNA-Rptr–tansfected promastigotes, ‘Our results indicate that our system may be 
useful for studying the pteridine salvage pathway in Leishmania as a possible drug target. 
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 Introduction: 
Leishmania are protozoan parasites that cause a spectrum of diseases termed 
leishmaniasis, which vary in severity from mild cutaneous to fatal visceral disease. 
Leishmania exhibit many unusual features, including the pteridine metabolic pathway, 
which is essential for growth. Thus, all parts of this pathway should be excellent targets 
for chemotherapeutic attack. As pteridine auxotrophs, Leishmania absolutely require an 
exogenous source in order to infect their mammalian hosts 1-3. 
To overcome this problem, Leishmania have evolved a complex and versatile pteridine 
salvage network capable of scavenging a wide array of conjugated and unconjugated 
pteridines, notably folate and biopterin, respectively 4. Folate and biopterin serve as co-
factors only in their fully reduced tetrahydro forms, H4-folate and H4-biopterin, 
respectively. 
In Leishmania and mammalian cells, H4-folate is generated from folate and dihydrofolate 
(H2-folate) by the NADPH-dependent enzyme dihydrofolate reductase (DHFR) 5. 
In Leishmania and other protozoa, DHFR occurs as a bifunctional enzyme, joined to 
thymidylate synthase (DHFR-TS) 6. The principal role of H4-folate is to serve as an 
essential co-factor in the de novo biosynthesis of thymidylate in Leishmania 7. In 
mammalian cells, H4-biopterin is synthesized de novo or salvaged through DHFR-
mediated reduction of H2-biopterin 8. 
In contrast, in Leishmania the de novo biopterin synthetic pathway is absent and DHFR-
TS shows no activity with biopterin or H2-biopterin. Instead, reduced biopterin is 
generated through the action of pteridine reductase 1 (PTR1), which sequentially reduces 
oxidized biopterin to H2-biopterin and then to H4-biopterin 3,9-11. 
PTR1 was identified as the gene within the Leishmania H region that, if overexpressed by 
gene amplification or DNA transfection, confers methotrexate (MTX) resistance 3,10. The 
predicted PTR1 protein shows homology to a large family of aldo/keto reductases and 
short-chain dehydrogenases, including several enzymes involved in pteridine metabolism, 
such as sepiapterin reductase 3 and dihydropteridine reductase (DHPR) 12. 
Despite the requirement of Leishmania for reduced folate and biopterin for growth, 
currently available anti-pteridines have not shown much promise clinically against 
leishmaniasis, even though they have proved effective against other protozoan infections’ 
13. Thus, there is great need for continued efforts and research in this area. In this study, 
we focus on the inhibition of PTR1 gene expression for the purposes of treating 
leishmaniasis. 
 
Materials and Methods 
DNA extraction and gene amplification: L. major was grown in NNN medium and 
cultured in RPMI-1640 enriched with 10% fetal bovine serum. Leishmania promastigotes 
were harvested by centrifugation and DNA was extracted. A set of primers (PTR F, 5´-
GGA TCC ATG ACT GCT CCG ACC-3´; PTR R, 5´-GGT ACC TCA GGC CCG GGT 
AAG-3´) was designed based on the published L. major ptr1 sequence (GenBank 
Accession No. L01699) with BamHI and KpnI restriction sites on the 5´-ends of the 
forward and reverse primers, respectively. The PTR1 coding region was amplified from 
genomic DNA and the PCR product was ligated to a 3´ T-tailed, EcoRV-digested 
pBluescript. 
Construction of the antisense PTR1 gene: The Leishmania major PTR1 gene (accession 
code EF113119) was cloned into pBluescript in the KpnI and BamHI recognition sites, 
hereafter referred to as pBSC-ptr 14.  This was used as the source of the L. major PTR1 
gene. Recombinant pBluescript was digested with KpnI and BamHI enzymes, after which 
the PTR1 gene DNA fragment was purified using a Fermentas DNA purification kit (cat. 
No. k0513) and subcloned into pcDNA3 digested with KpnI and BamHI. The eukaryotic 
expression vector pcDNA3 harbors a gene encoding neomycin resistance. The 
recombinant plasmid was transformed into the E. coli TOP10 strain. Because the PTR1 
gene is cloned antiparallel to the promoter, this expression plasmid is referred to as either 
pcDNA-Rptr or antisense. 
 
Transfection of Leishmania promastigotes:  L. major was cultured in liquid medium 199 
(Sigma, UK) supplemented with 10% defined heat-inactivated fetal bovine serum 
(Biosera), 10 mM adenine (Sigma, UK), 40 mM HEPES (Sigma, UK), 0.25% hemin 
(Sigma, UK), 100 mg/ml streptomycin (Biosera) and 100 IU/ ml penicillin (Biosera). 
Late logarithmic phase L. major promastigotes were harvested by centrifugation (1500×g, 
10 min) and resuspended at a concentration of 5 × 107/ml in ice-cold transfection buffer 
(21 mM HEPES, pH 7.5, 137 mM NaCl, 5 mM KCl, 0.7 mM Na2HPO4, 6 mM glucose). 
The promastigotes were divided into two groups: one group was transfected with 50 μg 
of pcDNA-Rptr (antisense), whereas the other group was electroporated with pcDNA3 
using a BioRad Gene Pulser at 450 V and 450 μF capacitance under conditions described 
previously 15- 17. Transfected and electroporated cells were cultured for 48 h in drug-free 
medium 199 and subsequently plated onto semi-solid medium 199 containing 40 μg/ml 
G418 (Sigma, UK) as a selective antibiotic 18,19. After two weeks, single colonies were 
mass cultured into medium 199 supplemented with 40 μg/mL neomycin. 
 
Inhibition of PTR1 expression: Transfected and untransfected L. major promastigotes 
were collected by centrifugation at 3000 g for 10 min and washed twice with 1x TBS 
(150 mM NaCl, 10 mM  Tris pH 7.5). Cells were suspended and sonicated in lysis buffer 
(50 mM Tris, 10% glycerol, 0.1% Triton X-100, 1 mM PMSF). Lysates were centrifuged 
at 1000 g for 10 min and the supernatants were taken for analysis. Western blot analysis 
was performed as described previously 20. Briefly, 106 of each transfected and 
untransfected L. major promastigotes were harvested and lysed by sonication. Protein 
samples were separated on 10% SDS-PAGE, transferred to nitrocellulose membranes and 
incubated with a 1:500 dilution of rabbit anti-PTR1 antibody 14 for 1 hour at 37 ºC.  Then, 
the membrane was incubated with horseradish peroxidase (HRP)-conjugated goat anti-
rabbit IgG (1:5000) as the secondary antibody. Antibody binding was visualized using 
diaminobenzidine (DAB) for one hour at 37 ºC. 
 
Results 
Figure 1 shows the PCR product of the L. major PTR1 gene. The gene was cloned into 
pBluescript, digested with Bam HI and KpnI, and subcloned into pcDNA3 as antisense 
(pcDNA-Rptr). To confirm the identity of the recombinant plasmid, pcDNA-Rptr was 
digested with the restriction enzymes KpnI and BamHI. An 866-bp insert and a 5.4-kb 
vector fragment were observed by electrophoresis [Fig. 2]. When pcDNA3 was digested 
with KpnI and BamHI, only the 5.4-kb vector fragment was observed [Fig. 3], indicating 
that the target fragment was inserted into the multiple cloning site of pcDNA3. 
 
Cells after transfection: Twenty-four hours after transfection, some dead cells were 
observed. After selection with 40 μg/mL G418, untransfected cells died, and transfected 
cells survived. The cell clones were isolated  10-14 days after G418 selection. 
 
Inhibition of PTR1 expression by antisense: Transfected and untransfected promastigotes 
were mass cultured. Promastigotes were harvested by centrifugation and lysed by 
sonication. Protein samples were separated on 10% SDS-PAGE, transferred to 
nitrocellulose membranes and analyzed using a rabbit anti-PTR1 primary antibody.  The 
PTR1 protein was expressed in untransfected promastigotes [Fig. 4, lane 1], but not in 
pcDNA3 Rptr–transfected promastigotes [Fig. 4, lane 2], indicating that the  gene was 
inhibited by the antisense construct. 
 Discussion  
The properties of PTR1 suggest several mechanisms to explain how its overproduction 
creates MTX resistance. Because PTR1 binds MTX tightly, it may sequester MTX from 
DHFR-TS 11.  In addition, PTR1 exhibits a broad specificity for pteridine substrates and 
reduces folate to the H2- and H4 forms 21. PTR1 may mediate MTX resistance through its 
ability to reduce folate to generate H2 folate, which is known to be extremely effective in 
relieving the inhibition of DHFR-TS by MTX in vitro 22- 24. 
Deletion of the PTR1 gene is lethal to the promastigote in the presence of MTX. This 
lethal effect can be countered by the provision of reduced pterins, but not folate [5]. 
Others have already done this, so we are doing it as well. In this study, pcDNA-Rptr was 
prepared and confirmed; the vector contains the PTR1 gene oriented antiparallel to the 
promoter. L. major promastigotes were transfected with pcDNA-Rptr or pcDNA3, and 
lysates were examined by western blot analysis, which showed that the expression of the 
PTR1 gene was inhibited by pcDNA-Rptr successfully. Our data are similar to those in a 
study by Chen et al., in which they used full-length antisense RNA to inhibit the 
expression of the gp63 gene in Leishmania amazonensis 25.  Although the targeted gene 
deletion in L. major GP63 reported by Joshi et al. 26, 27 is considered in the present 
investigation, our data demonstrate that inhibition occurs in the cytosol, as Dumas et al. 
reported in their study using cytosolic antisense RNA to regulate the expression of 
noncoding RNA in amastigotes 28.  Liang et al. demonstrated that small nucleolar RNA 
(snoRNA) genes can be silenced in L. major, Leptomonas collosoma and Trypanosoma 
brucei. Silencing is achieved in Leptomonas collosoma and L. major by expressing an 
antisense transcript complementary to the snoRNA gene, resulting in the accumulation of 
small interfering RNA (siRNA). The siRNA then eliminates the mature snoRNA 29. 
Other scientists have used antisense RNA to inhibit beta-tubulin synthesis in the 
Leishmania donovani amastigote 30, as well as a mini-exon sequence to inhibit amastigote 
growth 31-34.  In contrast to these previous studies, the present work is the first report on 
the inhibition of Leishmania PTR1 by a full-length antisense construct. Our results 
demonstrate that PTR1 antisense RNA can efficiently block PTR1 mRNA and protein 
expression in L. major promastigotes. This is a model for gene inhibition of 
LeishmaniaThey were confirmed previously in materiale and methods, and the approach 
that we report here may prove useful for creating similar model systems for studying 
other infectious organisms and cancers involving a single gene. 
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Figure legends 
 
 
Figure 1. Electrophoresis of PCR products on a 1% agarose gel. 
 Lane 1: The 866-bp PCR product of Leishmania major ptr1 gene 
 Lane 2: 100-bp DNA ladder marker  
 
 
Figure 2: Identification of recombinant plasmid pcDNA-Rptr using agarose gel electrophoresis. 
Lane 1:100-bp DNA ladder marker 
Lane 2: pcDNA-Rptr digested with KpnI and BamHI 
 
Figure 3: 1% agarose gel electrophoresis 
Lane 1: pcDNA3 digested with KpnI and BamHI 
Lane 2: 100-bp DNA ladder marker  
 
 
Figure 4: Western blot analysis to demonstrate lack of expression of PTR1 protein in 
antisense-transfected promastigotes’ Lane 1: Lysate of untransfected promastigotes (without 
antisense).  
Lane 2: Lysate of pcDNA-Rptr-transfected promastigotes (with antisense) 



